Bausch+Lomb IPO Presentation Deck

Growth momentum today with potential to accelerate with pipeline of innovation Pipeline of >100 projects across all B+L segments TODAY Vision Care Ophthalmic Pharmaceuticals Surgical BAUSCH + LOMB PreserVision LUMIFY REDNESS RELIEVER EYE SHOPS INFUSE Biotrue re- nu Boston Artelac FIZUALIN FLOMB Minims Visudyne LUX GOOD enVistatoric storz Ophthalmic Instruments 1. Potential treatment to slow progression of myopia in children 2. Indication for treatment of macular edema associated with uveitis slivecom LUIT A Daily SiHy (International) XIPERE Launching Now Xipere™ - Macular edema² eyeTELLIGENCE PIPELINE TO ACCELERATE GROWTH 3. Investigational treatment for dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) 4. Investigational treatment for reduction of pediatric myopía progression in children ages 3 to 12 INFUSE Multifocal & Toric lenses Bio true Eye hydration line NOV03 Dry eye treatment³ Cosmetic lenses Eyetelligence TM 3D Microscope Lux Premium Envista Premium digital ecosystem IOL Expansion IOL Expansion Ranibizumab biosimilar PIPELINE Wet AMD BAUSCH+LOME Virtual fitting platform for Ortho-K lenses ARISE ORTHO-K SYSTE Novel contact lenses for myopia in children¹ Low dose atropine spray Myopia progression4 Femto Excimer Laser (US) Cataract Laser Flap Laser Cataract / Retina Platform 35

View entire presentation